Prevention of bleeds in hemophilia patients with inhibitors: Emerging data and clinical direction

American Journal of Hematology

Volumn 77, Issue 2, 2004, Pages 187-193

  Leissinger, Cindy A ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hemophilia A; Immune tolerance therapy; Inhibitors; Prophylaxis; Prothrombin complex concentrates

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 INHIBITOR; FEIBA VH; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTHROPATHY; BLEEDING; DRUG COST; ERADICATION THERAPY; HEALTH CARE COST; HEMARTHROSIS; HEMOPHILIA; HUMAN; IMMUNE TOLERANCE THERAPY; IMMUNOLOGICAL TOLERANCE; INCIDENCE; PRIORITY JOURNAL; PROPHYLAXIS; SHORT SURVEY; THROMBOSIS; VIRUS INFECTION; VIRUS TRANSMISSION;

BLOOD COAGULATION FACTORS; CLINICAL TRIALS; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; IMMUNE TOLERANCE; ISOANTIBODIES; RECOMBINANT PROTEINS;

EID: 4644334185     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20162     Document Type: Short Survey

References (51)

1. Scharrer I, Bray G, Netzling O. Incidence of inhibitors in hemophilia A patients: a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999;5:145-154.
2. Lusher J. Factor VIII inhibitors with recombinant products: prospective clinical trials. Haemotologica 2000;85(Suppl 10):2-6.
3. Wight J, Paisley S. The epidemiology of inhibitors in hemophilia A: a systematic review. Haemophilia 2003;9:418-435.
4. Colowick AB, Bohn RL, Avom J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000;96:1698-1702.
5. Triemstra M, Rosendaal FR, Smit C, Van der Ploeg HM, Briet E. Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986. Ann Intern Med 1995;123:823-827.
6. Leissinger C, Wulff K, Abdou A. Inhibitor prevalence and association with morbidity in severe hemophilia A patients. Blood 2001;98:535a.
7. Oldenburg J, Brackmann HH, Schwaab. Risk factors for inhibitor development in hemophilia A. Haematologica 2000;85(Suppl 10): 7-13.
8. Schwaab R, Brackmann HH, Meyer C, et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995;74:1402-1406.
9. Hay CR, Ollier W, Pepper L, et al. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb Haemost 1997;77:234-237.
10. Oldenburg J, Picard J, Schwaab R, Brackmann HH, Tuddenham EGD, Simpson E. HLA genotype of patients with severe hemophilia A due to intron 22 inversions with and without inhibitors to factor VIII. Thromb Haemost 1997;77:238-242.
11. van der Bom JG, Mauser-Bunschoten EP, Fischer K, van den Berg HM. Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Thromb Haemost. 2003;89:475-479.
12. Lorenzo J, Lopez A, Altisent C, Aznar J. Incidence of factor VIII inhibitors in severe hemophilia: the importance of patient age. Br J Haematol 2001;113:600-603.
13. Aledort LM, DiMichele DM. Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia 1998;1:68.
14. Kruse-Jarres R, Wulff K, Leissinger C. Inhibitors in African Americans with severe hemophilia A. Blood 2003;102:799a.
15. Vermylen J. How do some hemophiliacs develop inhibitors? Haemophilia 1998;4:538-542.
16. Peerlinck K, Arnout J, Di Giambattista M, et al. Factor VIII inhibitors in previously treated hemophilia A patients with a double virus inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997;77:80-86.
17. Peerlinck K, Arnout J, Gilles JG, Saint-Remy J-M, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multi-transfused hemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993;69:115-118.
18. Kasper CK, Aledort L, Aronson D, et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975;34:612.
19. Lusher JM. Factor VIII inhibitors. Etiology, characterization, natural history, and management. Ann NY Acad Sci 1987;509:89-102.
20. Ho AY, Height SE, Smith MP. Immune tolerance therapy for haemophilia. Drugs 2000;60:547-554.
21. Brackmann HH, Effenberger W, Hess, L, Schwaab R, Oldenburg J. Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)? Eur J Haematol 1998;61(Suppl 63):18-23.
22. Hay CR, Lozier JN, Lee CA, et al. Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia A and inhibitors: the results of an international survey. Thromb Haemost 1996;75:25-29.
23. Turecek P, Varadi K, Gritsch H, et al. Factor Xa and prothrombin: mechanism of action of FEIBA. Vox Sang 1999;77(Suppl 1): 72-79.
24. Sjamsoedin LJ, Heijnen L, Mauser-Bunshoten EP, et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to Factor VIII. A double-blind clinical trial. N Engl J Med 1981;305:717-721.
25. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with Factor VIII and Factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997;77:1113-1119.
26. Leissinger CA. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors. Haemophilia 1999;5(Suppl 3):25-32.
27. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002;8:83-90.
28. Teitel JM. Recombinant factor VIIa versus aPCCs in haemophiliacs with inhibitors: treatment and cost considerations. Haemophilia 1999;5(Suppl 3):43-49.
29. Laurian Y, Girma JP, Lambert T, Meyer D, Larrieu MJ. Incidence of immune responses following 102 infusions of autoplex in 18 hemophilic patients with antibody to factor VIII. Blood 1984;63:457-462.
30. Lusher JM. Inhibitor antibodies to factor VIII and factor IX: management. Semin Thromb Hemost 2000;26:179-188.
31. Knight C, Paisley S, Wight J, Jones ML. Economic modeling of different treatment strategies for haemophilia A with high-responding inhibitors. Haemophilia 2003;9:521-540.
32. Brackmann HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 1977;2:933.
33. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors-twenty years' "Bonn protocol". Vox Sang 1996;70(Suppl 1):30-35.
34. DiMichele DM. Immune tolerance: a synopsis of the international experience. Haemophilia 1998;4:568-573.
35. DiMichele DM, Kroner BL. North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002;87:52-57.
36. Mariani G, Siragusa S, Kroner BL. Immune tolerance induction in hemophilia A: a review. Semin Thromb Hemost. 2003;29:69-76.
37. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe hemophilia A and B. J Intern Med 1992;232:25-32.
38. Funk M, Schmidt H, Escuriola-Ettingshausen C, et al. Radiological and orthopedic score in pediatric hemophilic patients with early and late prophylaxis. Ann Hematol 1998;77:171-174.
39. Kreuz W, Escuriola-Ettinghausen C, Funck M, Schmidt H, Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start? The German experience. Haemophilia 1998;4:413-417.
40. Penner JA. Treatment of inhibitor patients with activated prothrombin complex concentrates. Prog Clin Biol Res 1984;150:291-308.
41. Hutchinson RJ, Penner JA, Hensinger RN. Anti-inhibitor coagulant complex (Autoplex) in hemophilia inhibitor patients undergoing synovectomy. Pediatrics 1983;71:631-633.
42. Hanna WT, Madigan RR, Miles MA, Lange RD. Activated factor IX complex in treatment of surgical cases of haemophilia A with inhibitors. Thromb Haemost 1981;46:638-641.
43. Kurczinsky EM, Penner JA. Activated prothrombin concentrate for patients with factor VIII inhibitors. N Engl J Med 1974;291:164-167.
44. Abildgaard CF, Penner JA, Watson-Williams J. Anti-inhibitor coagulant complex (Autoplex) for treatment of factor VIII inhibitors in hemophilia. Blood 1980;56:978-984.
45. Hilgartner MW, Makipernaa A, Dimichele DM. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia 2003;9:261-268.
46. Valentino LA, Salit MG. Prophylactic use of FEIBA in children with hemophilia complicated by high-titered inhibitors. Blood 2002;100(Suppl):102B (abstract 3886).
47. Kreuz W, Escuriola-Ettinghausen C, Mentzer D, et al. Factor VIII inhibitor bypass activity (FEIBA) for prophylaxis during immune tolerance induction (ITI) in patients with high-responding inhibitors. Blood 2000;96:266a.
48. Kreuz W, Escuriola-Ettinghausen C, Martinez I, Mentzer D, Figura S, Klarmann D. Efficacy and safety of factor VIII inhibitor bypass activity (FEIBA) for long-term prophylaxis in patients with high-responding inhibitors. Blood 2000;96:265a.
49. Kulzer L, Kouides PA. Prophylactic treatment of severe FVIII deficiency with inhibitor with prothrombin complex concentrates. Hemaware 2001;6:4.
50. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994;236:391-399.
51. Molho P, Rolland N, Lebrun T, et al. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group. Haemophilia 2000;6:23-32.